HC Wainwright Forecasts Legend Biotech FY2026 Earnings

Legend Biotech logo with Healthcare background
Image from MarketBeat Media, LLC.

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) - Research analysts at HC Wainwright issued their FY2026 EPS estimates for Legend Biotech in a note issued to investors on Wednesday, November 11th. HC Wainwright analyst M. Kapoor anticipates that the company will earn $0.24 per share for the year. HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Legend Biotech's current full-year earnings is ($0.02) per share. HC Wainwright also issued estimates for Legend Biotech's Q1 2027 earnings at $0.14 EPS, Q2 2027 earnings at $0.22 EPS and FY2027 earnings at $1.18 EPS.

Several other equities research analysts have also recently weighed in on the company. JPMorgan Chase & Co. reduced their price target on Legend Biotech from $35.00 to $33.00 and set a "neutral" rating on the stock in a research note on Friday, October 9th. TD Cowen dropped their target price on shares of Legend Biotech from $29.00 to $24.00 and set a "hold" rating on the stock in a report on Wednesday, August 12th. Royal Bank Of Canada decreased their price target on shares of Legend Biotech from $56.00 to $50.00 and set an "outperform" rating for the company in a research note on Wednesday, November 11th. Raymond James Financial reissued an "outperform" rating and set a $58.00 price target on shares of Legend Biotech in a research report on Monday, July 27th. Finally, Weiss Ratings upgraded shares of Legend Biotech from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, November 9th. Nine investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Legend Biotech presently has a consensus rating of "Moderate Buy" and a consensus price target of $48.64.

Check Out Our Latest Report on LEGN

Legend Biotech Price Performance

Shares of NASDAQ:LEGN opened at $16.10 on Friday. The stock has a 50 day moving average price of $19.24 and a 200-day moving average price of $22.09. Legend Biotech has a 52-week low of $15.73 and a 52-week high of $37.50.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.13. Legend Biotech had a negative return on equity of 0.03% and a negative net margin of 0.02%. The business had revenue of $359.50 million for the quarter, compared to analysts' expectations of $361.46 million. During the same period in the previous year, the firm posted ($0.05) EPS. The business's revenue was up 32.0% on a year-over-year basis.

Insider Transactions at Legend Biotech

In other Legend Biotech news, CFO Carlos E. Santos sold 5,430 shares of Legend Biotech stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $9.14, for a total value of $49,630.20. Following the completion of the transaction, the chief financial officer directly owned 14,246 shares of the company's stock, valued at approximately $130,208.44. The trade was a 27.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the company's stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $9.46, for a total transaction of $258,920.20. Following the completion of the transaction, the director owned 52,731 shares in the company, valued at approximately $498,835.26. This represents a 34.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.02% of the company's stock.

Institutional Trading of Legend Biotech

Institutional investors have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. bought a new stake in Legend Biotech in the 2nd quarter worth about $55,307,000. Arrowstreet Capital Limited Partnership raised its holdings in shares of Legend Biotech by 343.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 406,901 shares of the company's stock valued at $7,361,000 after purchasing an additional 315,176 shares during the last quarter. Squarepoint Ops LLC raised its holdings in shares of Legend Biotech by 60.4% during the second quarter. Squarepoint Ops LLC now owns 769,252 shares of the company's stock valued at $22,216,000 after purchasing an additional 289,772 shares during the last quarter. Sei Investments Co. lifted its position in Legend Biotech by 215.4% during the first quarter. Sei Investments Co. now owns 324,921 shares of the company's stock valued at $5,878,000 after purchasing an additional 221,899 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Legend Biotech by 29.5% in the first quarter. Renaissance Technologies LLC now owns 521,800 shares of the company's stock worth $9,439,000 after purchasing an additional 119,000 shares during the last quarter. 70.89% of the stock is currently owned by hedge funds and other institutional investors.

Legend Biotech Company Profile

(Get Free Report)

Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson's Innovative Medicine business, which collaborates on its commercialization.

Further Reading

Earnings History and Estimates for Legend Biotech (NASDAQ:LEGN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Legend Biotech Right Now?

Before you consider Legend Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Legend Biotech wasn't on the list.

While Legend Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines